Related Experiment Video
Updated: Aug 19, 2026
In Vivo Calcium Imaging in C. elegans Body Wall Muscles
Published on: October 20, 2019
[The mutants of calcineurin transgenic mice]
1Department of Cardiovascular Science of Medicine, Chiba University Graduate School of Medicine.
Abstract:
It has been reported that the constitutively active form of calcineurin transgenic mice showed significant cardiac hypertrophy and heart failure, and that the development of cardiac hypertrophy in the transgenic mice was suppressed by inhibitors for calcineurin. We recently generated the transgenic mice overexpressing the dominant negative mutants of calcineurin specifically in the heart and observed in the transgenic mice that pressure overload-induced cardiac hypertrophy was significantly attenuated as compared to wild type mice.
Insights
Calcineurin activity drives cardiac hypertrophy. Inhibiting calcineurin or using dominant-negative mutants in heart-specific transgenic mice significantly reduces pressure overload-induced cardiac hypertrophy, offering potential therapeutic targets.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Signal Transduction
Context:
- Calcineurin is a key signaling molecule implicated in cardiac hypertrophy.
- Constitutively active calcineurin in transgenic mice leads to cardiac hypertrophy and heart failure.
- Calcineurin inhibitors have shown efficacy in suppressing cardiac hypertrophy development.
Purpose:
- To investigate the role of calcineurin in pressure overload-induced cardiac hypertrophy.
- To assess the effect of inhibiting calcineurin activity using dominant-negative mutants in a cardiac-specific manner.
Summary:
- Transgenic mice overexpressing dominant-negative calcineurin mutants specifically in the heart were generated.
- These mice exhibited significantly attenuated cardiac hypertrophy in response to pressure overload compared to wild-type controls.
- This suggests a critical role for calcineurin in the pathological cardiac remodeling process.
Impact:
- Provides evidence for calcineurin as a therapeutic target for heart failure and cardiac hypertrophy.
- Highlights the potential of dominant-negative strategies for modulating calcineurin signaling in the heart.
- Informs future research on calcineurin-dependent pathways in cardiovascular disease.
